Lauren A. Byers

24.9k total citations · 5 hit papers
202 papers, 8.8k citations indexed

About

Lauren A. Byers is a scholar working on Oncology, Molecular Biology and Epidemiology. According to data from OpenAlex, Lauren A. Byers has authored 202 papers receiving a total of 8.8k indexed citations (citations by other indexed papers that have themselves been cited), including 162 papers in Oncology, 97 papers in Molecular Biology and 48 papers in Epidemiology. Recurrent topics in Lauren A. Byers's work include Lung Cancer Research Studies (99 papers), Neuroendocrine Tumor Research Advances (46 papers) and Lung Cancer Treatments and Mutations (35 papers). Lauren A. Byers is often cited by papers focused on Lung Cancer Research Studies (99 papers), Neuroendocrine Tumor Research Advances (46 papers) and Lung Cancer Treatments and Mutations (35 papers). Lauren A. Byers collaborates with scholars based in United States, United Kingdom and Japan. Lauren A. Byers's co-authors include John V. Heymach, Charles M. Rudin, Don L. Gibbons, Carl M. Gay, Lixia Diao, Jing Wang, Ignacio I. Wistuba, John D. Minna, Triparna Sen and Kavitha Balaji and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Lauren A. Byers

193 papers receiving 8.8k citations

Hit Papers

Molecular subtypes of small cell lung cancer: a sy... 2014 2026 2018 2022 2019 2019 2014 2016 2023 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
    2019 718 citations Lauren A. Byers, John V. Heymach et al. profile →
  2. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
    2019 616 citations Triparna Sen, B. Leticia Rodriguez et al. Cancer Discovery profile →
  3. Small cell lung cancer: Where do we go from here?
    2014 453 citations Lauren A. Byers et al. profile →
  4. Epithelial–Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma
    2016 349 citations Yanyan Lou, Lixia Diao et al. Clinical Cancer Research profile →
  5. Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions
    2023 179 citations Carl M. Gay, Lauren A. Byers et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lauren A. Byers United States 46 6.0k 4.1k 2.1k 1.9k 1.5k 202 8.8k
Daniel Morgensztern United States 36 5.4k 0.9× 3.9k 1.0× 1.9k 0.9× 4.5k 2.4× 694 0.5× 228 10.4k
Jean‐Pierre Delord France 43 5.5k 0.9× 2.2k 0.5× 789 0.4× 2.0k 1.1× 1.7k 1.2× 260 8.4k
Robert L. Camp United States 56 5.7k 0.9× 6.2k 1.5× 1.2k 0.6× 2.3k 1.2× 1.3k 0.9× 118 12.8k
Massimo Roncalli Italy 59 4.7k 0.8× 3.2k 0.8× 2.1k 1.0× 3.3k 1.8× 1.6k 1.1× 228 11.5k
Alain C. Mita United States 46 3.4k 0.6× 3.7k 0.9× 731 0.4× 1.8k 1.0× 837 0.6× 210 8.1k
Naoko Takebe United States 38 3.2k 0.5× 4.3k 1.1× 1.1k 0.5× 925 0.5× 661 0.5× 181 7.4k
Alexander M. Menzies Australia 55 9.8k 1.6× 5.1k 1.2× 788 0.4× 2.5k 1.3× 3.2k 2.2× 330 12.6k
Peter S. Hammerman United States 42 3.0k 0.5× 4.3k 1.0× 540 0.3× 2.1k 1.1× 1.5k 1.0× 86 8.1k
Aatur D. Singhi United States 43 3.9k 0.6× 1.7k 0.4× 1.8k 0.9× 1.1k 0.6× 660 0.5× 225 6.8k
Amit Maity United States 45 2.7k 0.4× 3.4k 0.8× 511 0.2× 1.2k 0.6× 1.0k 0.7× 153 7.2k

Countries citing papers authored by Lauren A. Byers

Since Specialization
Citations

This map shows the geographic impact of Lauren A. Byers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lauren A. Byers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lauren A. Byers more than expected).

Fields of papers citing papers by Lauren A. Byers

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lauren A. Byers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lauren A. Byers. The network helps show where Lauren A. Byers may publish in the future.

Co-authorship network of co-authors of Lauren A. Byers

This figure shows the co-authorship network connecting the top 25 collaborators of Lauren A. Byers. A scholar is included among the top collaborators of Lauren A. Byers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lauren A. Byers. Lauren A. Byers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Concannon, Kyle, et al.. (2023). Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control. Molecular Cell. 83(5). 660–680. 30 indexed citations
2.
Ramkumar, Kavya, Azusa Tanimoto, Carminia M. Della Corte, et al.. (2023). Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer. Clinical Cancer Research. 29(16). 3237–3249. 14 indexed citations
3.
Konen, Jessica, B. Leticia Rodriguez, Joshua K. Ochieng, et al.. (2021). Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC. Cancer Research. 81(5). 1398–1412. 24 indexed citations
4.
Byers, Lauren A., Dmitry Bentsion, Steven Gans, et al.. (2021). Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study. Clinical Cancer Research. 27(14). 3884–3895. 52 indexed citations
5.
Ramkumar, Kavya, C. Allison Stewart, Kasey R. Cargill, et al.. (2020). AXL Inhibition Induces DNA Damage and Replication Stress in Non–Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors. Molecular Cancer Research. 19(3). 485–497. 38 indexed citations
6.
Atrafi, Florence, Harry J.M. Groen, Lauren A. Byers, et al.. (2018). A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors. Clinical Cancer Research. 25(2). 496–505. 38 indexed citations
7.
Sen, Triparna, Pan Tong, Lixia Diao, et al.. (2017). Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer. Clinical Cancer Research. 23(20). 6239–6253. 101 indexed citations
8.
Skinner, Heath D., Uma Giri, Liang Yang, et al.. (2017). Integrative Analysis Identifies a Novel AXL–PI3 Kinase–PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer. Clinical Cancer Research. 23(11). 2713–2722. 86 indexed citations
9.
Bono, Johann S. de, Ramesh K. Ramanathan, Lida A. Mina, et al.. (2017). Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. Cancer Discovery. 7(6). 620–629. 314 indexed citations
10.
Lou, Yanyan, Lixia Diao, Edwin R. Parra, et al.. (2016). Epithelial–Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. Clinical Cancer Research. 22(14). 3630–3642. 349 indexed citations breakdown →
11.
Skinner, Heath D., Uma Giri, Liang Yang, et al.. (2016). Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer. Clinical Cancer Research. 22(18). 4643–4650. 55 indexed citations
12.
Balaji, Kavitha, Smruthi Vijayaraghavan, Lixia Diao, et al.. (2016). AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers. Molecular Cancer Research. 15(1). 45–58. 70 indexed citations
13.
Ferrarotto, Renata, Suk Young Yoo, Pan Tong, et al.. (2015). Epithelial–Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor–Mediated Apoptosis in Non–Small Cell Lung Cancer. Clinical Cancer Research. 22(7). 1674–1686. 40 indexed citations
14.
Mazumdar, Tuhina, Lauren A. Byers, Patrick Kwok Shing Ng, et al.. (2014). A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma. Molecular Cancer Therapeutics. 13(11). 2738–2750. 66 indexed citations
15.
Cardnell, Robert J., Ying Feng, Lixia Diao, et al.. (2013). Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer. Clinical Cancer Research. 19(22). 6322–6328. 131 indexed citations
16.
Rabellino, Andrea, Brandon Carter, Georgia Konstantinidou, et al.. (2012). The SUMO E3-ligase PIAS1 Regulates the Tumor Suppressor PML and Its Oncogenic Counterpart PML-RARA. Cancer Research. 72(9). 2275–2284. 94 indexed citations
17.
Yang, Fei, Ximing Tang, Erick Riquelme, et al.. (2011). Increased VEGFR-2 Gene Copy Is Associated with Chemoresistance and Shorter Survival in Patients with Non–Small-Cell Lung Carcinoma Who Receive Adjuvant Chemotherapy. Cancer Research. 71(16). 5512–5521. 51 indexed citations
18.
Moeller, Benjamin J., John S. Yordy, Michelle D. Williams, et al.. (2011). DNA Repair Biomarker Profiling of Head and Neck Cancer: Ku80 Expression Predicts Locoregional Failure and Death following Radiotherapy. Clinical Cancer Research. 17(7). 2035–2043. 75 indexed citations
19.
Cai, Di, David S. Shames, Maria Gabriela Raso, et al.. (2010). Steroid Receptor Coactivator-3 Expression in Lung Cancer and Its Role in the Regulation of Cancer Cell Survival and Proliferation. Cancer Research. 70(16). 6477–6485. 48 indexed citations
20.
Kies, Merrill S., Floyd Christopher Holsinger, J. Jack Lee, et al.. (2009). Induction Chemotherapy and Cetuximab for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Results From a Phase II Prospective Trial. Journal of Clinical Oncology. 28(1). 8–14. 187 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniel Morgensztern Breakdown of academic impact, for papers by Jean‐Pierre Delord Breakdown of academic impact, for papers by Robert L. Camp Breakdown of academic impact, for papers by Massimo Roncalli Breakdown of academic impact, for papers by Alain C. Mita Breakdown of academic impact, for papers by Naoko Takebe Breakdown of academic impact, for papers by Alexander M. Menzies Breakdown of academic impact, for papers by Peter S. Hammerman Breakdown of academic impact, for papers by Aatur D. Singhi Breakdown of academic impact, for papers by Amit Maity
Rankless by CCL
2026